A new geometry of binding

Stop searching conformational space.
Collapse it.

ManifoldRx applies quantum geometric dimensional reduction to drug discovery. Instead of simulating billions of molecular configurations, we prove that binding dynamics converge to finite-dimensional invariant manifolds, then compute directly on them.

dim(𝒜λ) = d₀ < ∞   →   ΔGbind = minX ∈ 𝒜λ ⟨Hbind, ρ(X)⟩

The binding free energy computation reduces from infinite-dimensional conformational space to a finite manifold. Exponential convergence guaranteed.

Five theorems. One framework.

Each principle is formally proven and maps directly to a drug discovery bottleneck.

Principle I

λ-Attractor Dimensional Reduction

Complex protein-ligand systems evolve toward a Normally Hyperbolic Invariant Manifold where transverse fluctuations are exponentially suppressed. Binding free energy becomes a finite optimization problem.

Principle II

Entanglement Entropy Invariance

The entanglement entropy between protein and ligand subsystems becomes invariant under conformational scaling on the attractor. A rigorous criterion for binding mode stability across analog series.

Principle III

Curvature-Entanglement Correlation

Higher geometric curvature in binding pockets correlates with higher entanglement entropy. This quantifies druggability from geometry alone, before any simulation runs.

Principles IV–V

Spectral & Topological Completion

The final two principles complete the framework: spectral gap conditions for convergence guarantees, and topological invariants for classifying binding mode families.

A different starting point.

Classical Approach

  • Enumerate conformations, then filter
  • Billions of configurations evaluated
  • Convergence is slow and uncertain
  • Hardware-limited scaling
  • No mathematical convergence guarantee

ManifoldRx Approach

  • Prove the attractor exists, then compute on it
  • Finite-dimensional search space from the start
  • Exponential convergence with formal bounds
  • Complementary to quantum AND classical hardware
  • Mathematically rigorous error estimates

The numbers behind the problem.

$2.6B
Average cost per approved drug
1060
Possible drug-like molecules
90%
Clinical trial failure rate

The search space was never the answer.
The geometry was.

ManifoldRx is building the mathematical infrastructure to make drug discovery a problem of geometry, not enumeration. From first principles to first medicines.